# GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

> **NCT05797948** · NA · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Zanubrutinib
- **DRUG:** Lenalidomide
- **DRUG:** CD19/CD22 CAR-T
- **DRUG:** Azacitidine For Injection
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05797948
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05797948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05797948, "GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05797948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*